JP6033527B2 - 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的 - Google Patents

診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的 Download PDF

Info

Publication number
JP6033527B2
JP6033527B2 JP2010548040A JP2010548040A JP6033527B2 JP 6033527 B2 JP6033527 B2 JP 6033527B2 JP 2010548040 A JP2010548040 A JP 2010548040A JP 2010548040 A JP2010548040 A JP 2010548040A JP 6033527 B2 JP6033527 B2 JP 6033527B2
Authority
JP
Japan
Prior art keywords
certain embodiments
mir
fibrosis
modified
modified oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010548040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516410A5 (enExample
JP2011516410A (ja
Inventor
トーマス・トゥム
ヨハン・バウアーザックス
シュテファン・エンゲルハルト
カリナ・グロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of JP2011516410A publication Critical patent/JP2011516410A/ja
Publication of JP2011516410A5 publication Critical patent/JP2011516410A5/ja
Application granted granted Critical
Publication of JP6033527B2 publication Critical patent/JP6033527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
JP2010548040A 2008-02-27 2009-02-26 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的 Active JP6033527B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US3183508P 2008-02-27 2008-02-27
US61/031,835 2008-02-27
EP08003570.2 2008-02-27
EP20080003570 EP2096171A1 (en) 2008-02-27 2008-02-27 MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US3334008P 2008-03-03 2008-03-03
US61/033,340 2008-03-03
EPPCT/EP2009/051986 2009-02-19
PCT/EP2009/051986 WO2009106477A1 (en) 2008-02-27 2009-02-19 Microrna (mirna) and down-stream targets for diagnostic and therapeutic purposes
PCT/EP2009/001590 WO2009106367A1 (en) 2008-02-27 2009-02-26 Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014246185A Division JP2015107971A (ja) 2008-02-27 2014-12-04 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的

Publications (3)

Publication Number Publication Date
JP2011516410A JP2011516410A (ja) 2011-05-26
JP2011516410A5 JP2011516410A5 (enExample) 2013-01-17
JP6033527B2 true JP6033527B2 (ja) 2016-11-30

Family

ID=39639202

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010548040A Active JP6033527B2 (ja) 2008-02-27 2009-02-26 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的
JP2014246185A Pending JP2015107971A (ja) 2008-02-27 2014-12-04 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014246185A Pending JP2015107971A (ja) 2008-02-27 2014-12-04 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的

Country Status (23)

Country Link
US (10) US8236777B2 (enExample)
EP (3) EP2096171A1 (enExample)
JP (2) JP6033527B2 (enExample)
KR (1) KR101697482B1 (enExample)
CN (1) CN102027113B (enExample)
AU (1) AU2009218704C1 (enExample)
BR (1) BRPI0907565B1 (enExample)
CA (2) CA2716643C (enExample)
CY (1) CY1114426T1 (enExample)
DK (1) DK2260101T3 (enExample)
EA (1) EA020335B1 (enExample)
ES (1) ES2436885T3 (enExample)
HR (1) HRP20130766T1 (enExample)
IL (1) IL207704A (enExample)
ME (1) ME01600B (enExample)
MX (2) MX2010009346A (enExample)
MY (1) MY159454A (enExample)
NZ (1) NZ588185A (enExample)
PL (1) PL2260101T3 (enExample)
PT (1) PT2260101E (enExample)
SI (1) SI2260101T1 (enExample)
UA (1) UA100727C2 (enExample)
WO (2) WO2009106477A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US12319913B2 (en) 2018-10-31 2025-06-03 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534302T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
US20110190372A1 (en) * 2009-08-07 2011-08-04 New York University Compositions and methods for treating inflammatory disorders
CN102038959B (zh) * 2009-10-26 2012-12-19 中国科学院上海生命科学研究院 let-7/miR-98家族在制备治疗FAS基因相关疾病的药物中的应用
WO2011126842A2 (en) * 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
US20130150256A1 (en) 2010-06-11 2013-06-13 Jane Synnergren Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
WO2012012716A2 (en) * 2010-07-23 2012-01-26 Regulus Therapeutics, Inc. Targeting micrornas for the treatment of fibrosis
WO2012083005A2 (en) * 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
CN103620035B (zh) * 2011-04-25 2021-04-23 赛诺菲 用于调节mir-21活性的微rna化合物以及方法
CN104011208B (zh) * 2011-09-06 2020-04-10 马普科技促进协会 作为治疗靶的miRNA-212/132家族
KR20140091688A (ko) 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
EP2592145A1 (en) * 2011-11-11 2013-05-15 Medizinische Hochschule Hannover Medicament for the treatment of cardiac disease
MX2014006130A (es) * 2011-11-22 2015-04-13 Intermune Inc Metodos de diagnostico y tratamiento de la fibrosis pulmonar idiopatica.
CA2859430A1 (en) * 2011-12-13 2013-06-20 Ohio State Innovation Foundation Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
WO2013153082A1 (en) * 2012-04-10 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of nonalcoholic steatohepatitis
BR112014026639A8 (pt) * 2012-04-25 2018-01-16 Regulus Therapeutics Inc compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto.
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CA2782942C (en) * 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
WO2015003240A1 (en) 2013-07-12 2015-01-15 Canadian Blood Services Acellular pro-inflammatory compositions, process for making same and methods of using same
EP3060664B1 (en) 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
EP3079727A1 (en) * 2013-12-12 2016-10-19 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
WO2016004538A1 (en) 2014-07-10 2016-01-14 Canadian Blood Services Combination therapy of a cellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system
EP3201213B1 (en) * 2014-09-08 2021-06-02 Viridian Therapeutics, Inc. Mir-29 mimics and uses thereof
SG11201705907XA (en) 2015-01-20 2017-08-30 Miragen Therapeutics Inc Mir-92 inhibitors and uses thereof
CN106924757B (zh) * 2015-12-31 2020-07-24 中国科学院遗传与发育生物学研究所 miR-449c-5p及其拟似物在制备治疗和预防心脏瓣膜疾病产品中的应用
CN107034216A (zh) * 2016-02-04 2017-08-11 中国科学技术大学 miRancer分子的设计与应用
KR101835018B1 (ko) 2016-03-03 2018-03-06 고려대학교 산학협력단 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물
US11667916B2 (en) 2017-09-08 2023-06-06 Korea University Research And Business Foundation Composition for preventing or treating liver fibrosis, containing exosome or exosome-derived ribonucleic acid
CN107858419A (zh) * 2017-11-10 2018-03-30 青岛大学 miRNA的应用、应用其的产品及检测方法
US20210189398A1 (en) 2018-05-25 2021-06-24 Bioneer Corporation Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
CN109498642A (zh) * 2018-12-21 2019-03-22 复旦大学附属中山医院 一种柯萨奇b3病毒感染导致的心脏微血管病变的靶向治疗药物
KR20230008741A (ko) 2020-04-09 2023-01-16 테크니쉐 우니베르지테트 뮌헨 폐 섬유증 치료를 위한 miR-21 억제제의 대식세포로의 표적 전달
US20230302139A1 (en) * 2020-07-31 2023-09-28 University Of Florida Research Foundation, Incorporated Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna
WO2022184888A2 (en) * 2021-03-05 2022-09-09 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for use in the treatment of corneal dystrophies
KR102549208B1 (ko) * 2021-04-08 2023-06-30 연세대학교 산학협력단 심혈관 질환과 관련된 LncRNA 및 이의 용도
CN118667869B (zh) * 2024-07-10 2025-06-27 中国水稻研究所 水稻氮素利用基因nu4在调控水稻生长中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768139A (zh) * 2003-02-10 2006-05-03 独立行政法人产业技术总合研究所 通过dna干扰调控基因的表达
EP1606406B2 (en) * 2003-03-21 2013-11-27 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
CN1905876B (zh) * 2003-11-17 2010-06-09 诺瓦提斯公司 二肽基肽酶iv抑制剂的用途
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US20060142193A1 (en) * 2004-11-09 2006-06-29 Baylor College Of Medicine Selective inhibition of rock1 in cardiac therapy
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
CA3024953A1 (en) * 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2476762B1 (de) 2006-10-09 2014-01-08 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
AU2007333107A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US12319913B2 (en) 2018-10-31 2025-06-03 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Also Published As

Publication number Publication date
IL207704A0 (en) 2010-12-30
BRPI0907565B1 (pt) 2021-11-30
BRPI0907565A2 (pt) 2019-05-28
MX336299B (es) 2016-01-14
PT2260101E (pt) 2013-09-05
MY159454A (en) 2017-01-13
US20240189339A1 (en) 2024-06-13
US20210113603A1 (en) 2021-04-22
PL2260101T3 (pl) 2013-10-31
CY1114426T1 (el) 2016-08-31
EP2096171A1 (en) 2009-09-02
US20230028937A1 (en) 2023-01-26
ME01600B (me) 2014-09-20
US8236777B2 (en) 2012-08-07
EP2260101A1 (en) 2010-12-15
MX2010009346A (es) 2010-12-20
US20130018084A1 (en) 2013-01-17
JP2015107971A (ja) 2015-06-11
DK2260101T3 (da) 2013-08-19
CN102027113A (zh) 2011-04-20
US20170304347A1 (en) 2017-10-26
EP2260101B1 (en) 2013-05-29
AU2009218704C1 (en) 2015-01-29
US20110071211A1 (en) 2011-03-24
AU2009218704A1 (en) 2009-09-03
HK1150857A1 (en) 2012-01-13
CA3123067A1 (en) 2009-09-03
EP2628800A1 (en) 2013-08-21
CA2716643A1 (en) 2009-09-03
US20160177302A1 (en) 2016-06-23
CN102027113B (zh) 2017-08-18
US10434117B2 (en) 2019-10-08
WO2009106367A1 (en) 2009-09-03
NZ588185A (en) 2012-11-30
KR20100126430A (ko) 2010-12-01
JP2011516410A (ja) 2011-05-26
US9220722B2 (en) 2015-12-29
UA100727C2 (ru) 2013-01-25
SI2260101T1 (sl) 2013-10-30
EA020335B1 (ru) 2014-10-30
US10028974B2 (en) 2018-07-24
KR101697482B1 (ko) 2017-01-18
EA201070992A1 (ru) 2011-04-29
HRP20130766T1 (hr) 2013-10-25
US20140121264A1 (en) 2014-05-01
WO2009106477A1 (en) 2009-09-03
US8592389B2 (en) 2013-11-26
ES2436885T3 (es) 2014-01-07
US9663788B2 (en) 2017-05-30
IL207704A (en) 2016-11-30
CA2716643C (en) 2021-08-03
US20200069720A1 (en) 2020-03-05
AU2009218704B2 (en) 2014-09-18
US20180360866A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
JP6033527B2 (ja) 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的
TWI647235B (zh) 微型ｒｎａ（ｍｉｃｒｏｒｎａ）化合物及調節ｍｉｒ－２１活性之方法
JP5535076B2 (ja) 肝臓癌を治療するための標的化ミクロｒｎａ
TW201811812A (zh) 微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法
AU2014256406A1 (en) MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
HK1156360B (en) Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes
HK1156360A (en) Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes
HK1188611A (en) Microrna (mirna) mir-21 for diagnostic and therapeutic purposes
RS52904B (sr) Mikrornk (mirnk) mir-21 za dijagnozu i terapeutske svrhe
HK1150857B (en) Microrna (mirna) mir-21 for diagnostic and therapeutic purposes
HK1170768A1 (zh) 用於代谢紊乱的靶向微小rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140805

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161026

R150 Certificate of patent or registration of utility model

Ref document number: 6033527

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250